Puerto Rico Racial & Ethnic Minority Acceleration Consortium for Health Equity (PR-REACH)

波多黎各种族

• 批准号: 10820281
• 负责人: Karen G. Martinez Gonzalez
• 金额: $ 37.4万
• 依托单位: UNIVERSITY OF PUERTO RICO MED SCIENCES
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-06-01 至 2025-05-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10820281
• 关键词: Puerto; Rico; Racial; Ethnic; Minority

ABSTRACT This proposal seeks the establishment of the Puerto Rico Racial & Ethnic Minority Acceleration Consortium for Health Equity (PR-REACH). This consortium aims to support the advancement of Hispanic Puerto Ricans voices regarding perspectives, preferences, and unmet needs to FDA-approved medications and its outcomes, by increasing the available knowledge of individuals from this underrepresented group. The creation of this consortium (PR-REACH) is a first step in a research agenda to collaborate with the Food and Drug Administration (FDA) Office of Minority Health and Health Equity (OMHHE) across REACH research projects and activities. A training component is also sought that supports these by educating not only researchers, but also patients, students, providers and providers in training. The proposal has two aims, first to build an administrative research and communication infrastructure to support, collaborate and coordinate efforts between PR-REACH and the FDA OMHHE. To this end a PR-REACH leadership team, three research cores, a training and mentoring core, and an advisory team will be created to: 1) employ innovative strategies, trainings, education, and communication methods to understand Puerto Rican individuals preferences, experiences and unmet needs regarding FDA approved treatments and medications, 2) leverage big data, machine learning and artificial intelligence data analysis and local health data sources in PR to be able to evaluate the safety and efficacy of FDA-approved products (therapeutics, diagnostics, and vaccines) and products subject to EUAs/EUA expansion, and 3) identify barriers to clinical trial enrollment for Hispanic Puerto Ricans and develop innovative strategies to address such barriers. Finally, a pilot study under this consortium will be conducted (aim 2) to advance the understanding of substance use disorder patients’ journey as perspectives, preferences and unmet needs regarding substance use disorder (SUD) treatment with FDA approved medications in PR to be able to improve its outcomes. The PR-REACH will initiate with Hispanics living in Puerto Rico as a model than can inform and guide subsequent extrapolation to Hispanics in the US. These activities will be conducted in a 2-year period.

摘要 该提案寻求建立波多黎各种族和少数族裔加速联合会， 健康公平（PR-REACH）。该联盟旨在支持西班牙裔波多黎各人的进步 关于FDA批准的药物及其结果的观点，偏好和未满足的需求的声音， 通过增加这一代表性不足群体中个人的可用知识。设立这个 联合体（PR-REACH）是研究议程的第一步， 少数民族健康和健康公平办公室（OMHHE）跨REACH研究项目 和活动.还寻求培训部分，不仅通过教育研究人员， 还有病人、学生、提供者和培训提供者。该提案有两个目标，首先是建立一个 行政研究和通信基础设施，以支持、合作和协调各项努力 PR-REACH和FDA OMHHE之间的关系。为此，一个PR-REACH领导团队，三个研究核心， 将建立一个培训和指导核心以及一个咨询小组，以：1）采用创新战略， 培训，教育和沟通方法，以了解波多黎各人的喜好， 关于FDA批准的治疗和药物的经验和未满足的需求，2）利用大数据， 机器学习和人工智能数据分析以及PR中的本地健康数据源， 评估FDA批准的产品（治疗剂、诊断剂和疫苗）的安全性和有效性， EUA/EUA扩展的产品，以及3）确定西班牙裔波多黎各人临床试验入组的障碍 我们的目标是帮助哥斯达黎加人和制定创新战略来消除这些障碍。最后，在该联合体下进行的试点研究 将进行（目标2），以促进对物质使用障碍患者的旅程的理解， FDA关于物质使用障碍（SUD）治疗的观点、偏好和未满足的需求 在PR中批准的药物能够改善其结果。PR-REACH将针对西班牙裔发起 生活在波多黎各作为一个模型，比可以通知和指导随后的外推到西班牙裔在美国。 这些活动将在2年内进行。